AstraZeneca's shares are up 0.1% as investors prepare for vaccine data

Shares of AstraZeneca AZN, -0.88% were active in premarket trading on Monday as investors prepare for the release of Phase 1 clinical trial data for the COVID-19 vaccine candidate being developed by the drugmaker and the U.K.'s University of Oxford. The first set of trial data is expected to be published Monday in The Lancet, a British medical journal, according to Reuters. AstraZeneca's stock was up 0.1% before the market opened. This vaccine candidate is considered one of the frontrunners, alongside experimental vaccines being developed by Moderna Inc. MRNA, -4.10% and Pfizer PFE, -0.38% and BioNTech BNTX, -0.75%, in the race to develop a vaccine that can protect against coronavirus infections. AstraZeneca's stock has gained 18.8% year-to-date, in comparison to the S&P 500 SPX, -1.53%, which is down 0.2%.